1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8598173
APP PUB NO 20130053390A1
SERIAL NO

13661975

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to novel quioxaline-piperazine compounds, 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives of formula (1):

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
OCUPHIRE PHARMA INC37000 GRAND RIVER AVE SUITE 120 FARMINGTON HILLS MI 48335

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ahn, Chang Ho Rockville, US 12 25
Gong, Young-Dae Daejeon, KR 8 15
Jeon, Moon-Kook Daejeon, KR 5 15
Kim, Dong-Su Seoul, KR 46 634
Kim, Gun-Do Daejeon, KR 3 14
Kong, Jae Y Daejeon, KR 2 11
Lee, Young Bok Rockville, US 49 159

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 3, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00